VIP as a potential therapeutic agent in Gram negative sepsis

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 12, Issue 4, 2012, Pages 308-315

  Ibrahim, Hiba ^a   Barrow, Paul ^a   Foster, Neil ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Cytokine; Inflammation; Sepsis; Transcription bacteria; VIP

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; PATTERN RECOGNITION RECEPTOR; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

GRAM NEGATIVE SEPSIS; HORMONE SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MONOCYTE; NONHUMAN; REVIEW; SALMONELLA; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LIPOPOLYSACCHARIDES; SEPSIS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84870213550     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/187153012803832611     Document Type: Review

References (68)

1. Harrison, D.A.; Welch, C.A. and Eddleston, J.M. (2006) The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit. Care, 10, R42.
2. Martin, G.S.; Mannino, D.M.; Eaton, S. and Moss, M. (2003) The epidemiology of sepsis in the United States from 1979 through 2000.N. Engl. J. Med., 348, 1546-1554.
3. Melamed, A. and Sorvillo, F.J. (2009) The burden of sepsisassociated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit. Care, 13, R28.
4. Angus, D.C.; Linde-zwirble, W.T.; Lidicker, J.; Clermont, G.; Carcillo, J. and Pinsky, M.R. (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit. Care Med., 29, 1303-1310.
5. Ulloa, L. and Tracey, K.J. (2005) The "cytokine profile": a code for sepsis. Trends Mol. Med., 11, 56-63.
6. Remick, D.G.; Bolgos, G.; Copeland, S. and Siddiqui, J. (2005) Role of Interleukin-6 in Mortality from and Physiologic Response to Sepsis. Infect. Immun., 73, 2751-2757.
7. Wang, H.; Bloom, O.; Zhang, M.; Vishnubhakat, J.M.; Ombrellino, M.; Che. J.; Frazier, A.; Yang, H.; Ivanova, S.; Borovikova, L.; Manogue, K.R.; Faist, E.; Abraham, E.; Andersson, J.; Andersson, U.; Molina, P.E.; Abumrad, N.N.; Sama, A. and Tracey, K.J. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science, 285, 248-251.
8. Andersson, U. and Tracey, K.J. (2003) HMGB1 in sepsis. Scand. J. Infect. Dis., 35, 577-584.
9. Cauwels, A. and Brouckaert, P. (2011) Nitrite regulation of shock. Cardiovasc. Res., 89, 553-559.
10. Tang, H.; Ivanciu, L.; Popescu, N.; Peer, G.; Hack, E.; Lupu, C.; Taylor, F.B. and Lupu, F. (2007) Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am. J. Pathol., 171, 1066-1077.
11. Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 11, 373-384.
12. Yu, T.D.; Black, E.; Sands, K.E.; Schwartz, J.S.; Hibberd, P.L.; Graman, P.S.; Lanken, P.N.; Kahn, K.L.; Snydman, D.R.; Parsonnet, J.; Moore, R.; Platt, R. and Bates, D.W. (2003) Severe Sepsis: Variation in resource and therapeutic modality use among academic centres. Crit. Care., 3, R24-34.
13. Svenson, S. and Tomalia, D.A. (2005) Dendrimers in biomedical applications-reflections on the field. Adv. Drug Delivery Rev., 57, 2106-2129.
14. Cohen J. (1999) Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull., 55, 212-226.
15. Warren, H.S.; Suffredini, A.F.; Eichacker, P.Q. and Munford, R.S. (2002) Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med., 347, 1027-1030.
16. Tidswell, M.; Tillis, W.; Larosa, S.P.; Lynn, M.; Wittek, A.E.; Kao, R.; Wheeler, J.; Gogate, J. and Opal, S.M. (2010) Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit. Care Med., 38, 72-83.
17. Shaunak, S.; Thomas, S.; Gianasi, E.; Godwin, A.; Jones, E.; Teo, I.; Mireskandari, K.; Luthert, P.; Duncan, R.; Patterson, S.; Khaw, P. and Brocchini, S. (2004) Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nature Biotech., 22, 977-984.
18. Zongze, Z.; Jia, Z.; Chang, C.; Kai, C. and Yanlin, W. (2010) Protective effects of remifentanil on septic mice. Mol. Biol. Rep., 37, 2803-2808.
19. Shingu, C.; Hagiwara, S.; Iwasaka, H.; Matsumoto, S.; Koga, H.; Yokoi, I. and Noguchi, T. (2011) EPCK1, a Vitamin C and E Analogue, Reduces Endotoxin-Induced Systemic Inflammation in Mice. J. Surg. Res., 171, 719-725.
20. Harmar, A.J.; Arimura, A.; Gozes, I.; Journot, L.; Laburthe, M.; Pisegna, J.R.; Rawlings, S.R.; Robberecht, P.; Said, S.I.; Sreedharan, S.P.; Wank, S.A. and Waschek, J.A. (1998) International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev., 50, 265-270.
21. Dickson, L. and Finlayson, K. (2009) VPAC and PAC receptors: From ligands to function. Pharmacol. Ther., 121, 294-316.
22. Smalley, S.R.G.; Barrow, P.A. and Foster, N. (2009) Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin. Exp. Immunol., 157, 225-234.
23. Delgado, M. and Ganea, D. (2001) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide regulated NF-NB at multiple levels. J. Biol. Chem., 276, 369-380.
24. Lara-Marquez, M.L.; O'Dorisio, M.S. and Karacay, B. (2000) Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes. Ann. N. Y. Acad. Sci., 921, 45-54.
25. Kojima, M.; Ito, T.; Oono, T.; Hisano, T.; Igarashi, H.; Arita, Y.; Kawabe, K.; Coy, D.H.; Jensen, R.T. and Nawata, H. (2005) VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas, 30, 62-70.
26. Delgado, M.; Munoz-Elias, E.J.; Gomariz, R.P. and Ganea, D. (1999) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J. Immunol., 162, 4685-4696.
27. Ganea, D. and Delgado, M. (2002) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit. Rev. Oral Biol. Med., 13, 229-237.
28. Xin, Z. and Sriram, S. (1998) Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J. Neuroimmunol., 89, 206-212.
29. Delgado, M. and Ganea, D. (2001) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-cB, NF-AT, and early growth factors 2/3. J. Immunol., 166, 1028-1040.
30. Yang, X-J.; Ogyzko, V.V.; Nishikawa, J.; Howard, B.H. and Nakatani, Y. A. (1996) p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature, 382, 319-324.
31. Foster, N.; Hulme, S.D. and Barrow, P.A. (2005) Inhibition of IFNgamma-stimulated proinflammatory cytokines by vasoactive intestinal peptide (VIP) correlates with increased survival of Salmonella enterica serovar typhimurium phoP in murine macrophages. J. Interferon Cytokine Res., 25, 31-42.
32. Foster, N.; Hulme, S.D. and Barrow, P.A. (2006) Vasoactive intestinal peptide (VIP) prevents killing of virulent and phoP mutant Salmonella typhimurium by inhibiting IFN-gamma stimulated NADPH oxidative pathways in murine macrophages. Cytokine, 36, 134-140.
33. Foster, N.; Hulme, S.D. and Barrow, P.A. (2003) Induction of antimicrobial pathways during early-phase immune response to Salmonella spp. in murine macrophages: gamma interferon (IFNgamma) and upregulation of IFN-gamma receptor alpha expression are required for NADPH phagocytic oxidase gp91-stimulated oxidative burst and control of virulent Salmonella spp. Infect. Immun., 71, 4733-4741.
34. Delgado, M. and Ganea, D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-cB, NF-AT, and early growth factors 2/3. J. Immunol., 166, 1028-1040.
35. Foster. N.; Cheetham, J.; Taylor, J.J. and Preshaw, P.M. (2005) VIP inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J. Dent. Res., 84, 999-1004.
36. Foster, N.; Andreadou, K.; Jamieson, L.; Preshaw, P.M. and Taylor, J.J. (2007) VIP inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in monocytes. J. Dent. Res., 86, 883-887.
37. Kim, S.H.; Eisenstein, M.; Reznikov, L.; Fantuzzi, G.; Novick, D.; Rubinstein M. and Dinarello, C.A. (2000). Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA, 97, 1190-1195.
38. Novick, D.; Schwartsburd, B.; Pinkus, R.; Suissa, D.; Belzer, I.; Sthoeger, Z.; Keane, W.F.; Chvatchko, Y.; Kim, S.H.; Fantuzzi, G.; Dinarello, C.A. and Rubinstein M. (2001) A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine, 14, 334-342.
39. Zenz, R. and Wagner, E.F. (2006) Jun signalling in the epidermis: From developmental defects to psoriasis and skin tumors. Int. J. Biochem. Cell Biol., 38, 1043-1049.
40. Mackman, N.; Brand, K. and Edgington, T.S. (1991) Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J. Exp. Med., 174, 1517-1526.
41. Xie, Q.W.; Whisnant, R. and Nathan, C. (1993) Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med., 177, 1779-1784.
42. Zenz, R.; Eferl, R.; Scheinecker, C.; Redlich, K.; Smolen, J.; Schonthaler, H.B.; Kenner, L.; Tschachler, E. and Wagner, E.F. (2008) Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther., 10, 201-211.
43. Delgado, M. and Ganea, D. (2000) Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signalling pathway in LPS-stimulated macrophages. J. Neuroimmunol., 110, 97-105.
44. Foster, N.; Lea, S.R.; Preshaw, P.M. and Taylor, J.J. (2007) Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J. Leukoc. Biol., 81, 893-903.
45. Leceta, J.; Martínez, C.; Delgado, M.; Garrido, E. and Gomariz, R.P. (1996) Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol., 6, 29-36.
46. Vassiliou, E.; Jiang, X.; Delgado, M. and Ganea, D. (2001) TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch. Physiol. Biochem., 109, 365-368.
47. Liu, L.; Yen, J.H. and Ganea D. (2007) A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation. Peptides, 28, 1814-1824.
48. Delgado, M. and Ganea, D. (2001) VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. Arch. Physiol. Biochem., 109, 372-376.
49. Delgado, M.; Gonzalez-Rey, E. and Ganea, D. (2004) VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J., 18, 1453-1455.
50. Delgado, M.; Chorny, A.; Gonzalez-Rey, E. and Ganea, D. (2005) Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J. Leukoc. Biol., 78, 1327-1338.
51. Brandtzaeg, P.; Øktedalen, O.; Kierulf, P. and Opstad, P.K. (1989) Elevated VIP and plasma endotoxin in human Gram-negative septic shock. Regul. Pept., 24, 37-44.
52. Brandtzaeg, P.; Bjerre, A.; Øvstebø, R.; Brusletto, B.; Joø, G.B. and Kierulf, P. (2001) Neisseria meningitidis lipopolysaccharides in human pathology. J. Endotoxin. Res., 7, 401-420.
53. Revhaug, A.; Lygren, I.; Lundgren, T.I.; Andersen, O.K.; Burhol, P.G. and Giercksky, K.E. (1985) Increased plasma levels of vasoactive intestinal polypeptide in pigs during endotoxinaemia. Eur. Surg. Res., 17, 75-82.
54. Fuortes, M.; Blank, M.A.; Scalea, T.M.; Pollock, T.W. and Jaffe, B.M. (1988) Release of vasoactive intestinal peptide during hyperdynamic sepsis in dogs. Surgery, 104, 894-898.
55. Montegut, W.; Lowry, S.F. and Moldawer, L.L. (1995) Role of cytokines in septic shock and shock-related syndromes. B. B. Aggerwal, and R. K. Puri, eds. Human Cytokines: Their Role in Disease and Therapy 381. Blackwell Science, Cambridge.
56. Hamidi, S.A.; Szema, A.M.; Lyubsky, S.; Dickman, K.G.; Degene, A.; Mathew, S.M.; Waschek, J.A. and Said, S.I. (2006) Clues to VIP function from knockout mice. Ann. N. Y. Acad. Sci., 1070, 5-9.
57. Delgado, M.; Martinez, C.; Pozo, D.; Calvo, J.R.; Leceta, J.; Ganea, D. and Gomariz, R.P. (1999) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J. Immunol., 162, 1200-1205.
58. Delgado, M.; Martinez, C.; Pozo, D.; Calvo, J.R.; Leceta, J.; Ganea, D. and Gomariz, R.P. (1999) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J. Immunol., 162, 1200-1205.
59. Chorny, A. and Delgado, M. (2008) Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1. Am. J. Pathol. 172, 1297-1307.
60. Qiu, J.F.; Zhang, Z.Q.; Chen, W. and Wu, Z.Y. (2007) Protective effects of vasoactive intestinal peptide on septic shock rats. Zhonghua Wai Ke Za Zhi, 45, 196-199.
61. Krishnadas, A.; Onyüksel, H. and Rubinstein, I. (2003) Interactions of VIP, secretin and PACAP (1-38) with phospholipids: a biological paradox revisited. Curr. Pharm. Des., 9, 1005-1012.
62. Rubinstein, I. (2005) Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension. Expert. Rev. Cardiovasc. Ther., 3, 565-569.
63. Sethi, V.; Onyüksel, H. and Rubinstein, I. (2005) Liposomal vasoactive intestinal peptide. Methods Enzymol., 391, 377-395.
64. Hajos, F.; Stark, B.; Hensler, S.; Prassl, R. and Mosgoeller, W. (2008) Inhalable liposomal formulation for vasoactive intestinal peptide. Int. J. Pharm., 357, 286-294.
65. Foster, N. and Hirst, B.H. (2005) Exploiting receptor biology for vaccination with biodegradable particulates. Adv. Drug Deliv. Rev., 57, 431-450.
66. Fields, P.I.; Swanson, R.V.; Haidaris, C.G. and Heffron, F. (1986) Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc. Natl. Acad. Sci. USA, 83, 5189-5193.
67. Miller, S. I. and Mekalanos, J.J. (1990) Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages. J. Bacteriol., 172, 2485-2490.
68. Groisman, E. A. and Saier, M.H. (1990) Salmonella virulence: new clues to intramacrophage survival. Trends Biochem. Sci., 15, 30-33.